|
Isabelle de Cremoux (38, 4 children, graduated from Ecole Centrale de Paris, DECF and ISEB in London) joined SEVENTURE (500 million Euro capital fund) in July 2001 as a General Partner, Director of Lifesciences Department.
She started her career in 1991 at ARTHUR ANDERSEN Detroit, US and later moved to PFIZER France and PFIZER Europe, where she held several positions during 6 years in the field of management accounting, clinical research and Business Development.
In 1998 she became Associate Director of Business Development at FOURNIER in charge of licensing products and technologies as well as acquisitions and signed quite a few deals in Europe and in the US. Isabelle de Cremoux is a board member of Fluxome Sciences (DK), Vivostat (DK), Meristem Therapeutics (F) and manages the investment in DMS (F), Noxxon pharma (Germany) and Santaris pharma (DK).
Her track record includes Metabolic Explorer as lead investor: Metabolic Explorer was the 1st European IPO in white biotech and one of the best IPO venture capital financed lifesciences companies in France. Her track record also includes OPI PHARMA as lead investor, which realized one of the best trade sales in cash in France.
|
/Isabelle.jpg)
